Insulin Lispro Injection
Eli Lilly and Co.
Open FDA's page for this record- Discontinued date
- 09/01/2026
- Update type
- New
- Initial posting date
- 09/01/2026
- Package NDC
- 0002-7752-05
- Generic name
- Insulin Lispro Injection
- Contact info
- 800-545-5979
- Update date
- 09/01/2026
- Dosage form
- Injection
- Presentation
- Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05)
- Company name
- Eli Lilly and Co.
- Status
- To Be Discontinued
- Related info
A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
- Therapeutic category
- Endocrinology/Metabolism
- Harmonized identifiers (openFDA)
- Application number
- BLA020563
- Brand name
- INSULIN LISPRO JUNIOR KWIKPEN
- Generic name
- INSULIN LISPRO
- Manufacturer name
- Eli Lilly and Company
- Product NDC
- 0002-7752, 0002-7737, 0002-8222
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- SUBCUTANEOUS
- Substance name
- INSULIN LISPRO
- RxCUI
- 242120, 1652639, 1926331
- SPL ID
- 6329aa6b-3571-4196-83b0-fc99de56f3ab
- SPL set ID
- 97d5e596-aae1-42c9-ae89-c3780959c467
- Package NDC
- 0002-7737-01, 0002-8222-01, 0002-8222-59, 0002-7752-01, 0002-7752-05
- Nui
- N0000004931, N0000175453
- Pharm class cs
- Insulin [Chemical/Ingredient]
- Pharm class epc
- Insulin Analog [EPC]
- UNII
- GFX7QIS1II